Apigenin as an emerging hepatoprotective agent: current status and future perspectives

被引:3
作者
Wang, Cheng [1 ,2 ]
Feng, Xiaoli [1 ,3 ]
Li, Wen [1 ,2 ]
Chen, Li [1 ,2 ]
Wang, Xinming [1 ,2 ]
Lan, Yimiao [1 ,2 ]
Tang, Rong [4 ]
Jiang, Ting [1 ,2 ]
Zheng, Lingli [1 ,2 ]
Liu, Gang [1 ,2 ]
机构
[1] Chengdu Med Coll, Sch Clin Med, Chengdu, Peoples R China
[2] Chengdu Med Coll, Dept Pharm, Affiliated Hosp 1, Chengdu, Peoples R China
[3] Chengdu Med Coll, Dept Resp & Crit Care Med, Affiliated Hosp 1, Chengdu, Peoples R China
[4] Sichuan Univ, Coll Foreign Languages & Cultures, Chengdu, Peoples R China
关键词
apigenin; liver disease; hepatoprotection; toxicity; pharmacokinetics; new formulations; INDUCED LIVER-INJURY; HEPATOCELLULAR-CARCINOMA; OXIDATIVE STRESS; PPAR-GAMMA; CARBON-TETRACHLORIDE; SOLID DISPERSIONS; INDUCED APOPTOSIS; UP-REGULATION; IN-VITRO; HEPATOTOXICITY;
D O I
10.3389/fphar.2024.1508060
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Apigenin (C15H10O5, API) is a natural flavonoid widely found in vegetables, fruits, and plants such as celery, oranges, and chamomile. In recent years, API has attracted considerable attention as a dietary supplement due to its low toxicity, non-mutagenic properties and remarkable therapeutic efficacy in various diseases. In particular, evidence from a large number of preclinical studies suggests that API has promising effects in the prevention and treatment of a variety of liver diseases, including multifactorial liver injury, non-alcoholic fatty liver disease/non-alcoholic steatohepatitis, liver fibrosis and liver cancer. This paper provides a comprehensive review of the progress of research into the therapeutic applications of API in liver diseases as of August 2024, based on literature retrieved from databases such as Web of Science, PubMed, CNKI, Google Scholar and ScienceDirect. The hepatoprotective effects of API involve multiple molecular mechanisms, including inhibition of inflammation, alleviation of hepatic oxidative stress, amelioration of insulin resistance, promotion of fatty acid oxidation, inhibition of liver cancer cell proliferation and differentiation, and induction of tumour cell apoptosis. More importantly, signaling pathways such as Nrf2, NF-kappa B, PI3K/Akt/mTOR, NLRP3, Wnt/beta-catenin, TGF-beta 1/Smad3, AMPK/SREBP, PPAR alpha/gamma, MAPKs, and Caspases are identified as key targets through which API exerts its beneficial effects in various liver diseases. Studies on its toxicity and pharmacokinetics indicate that API has low toxicity, is slowly metabolized and excreted in vivo, and has low oral bioavailability. In addition, the paper summarises and discusses the sources, physicochemical properties, new dosage forms, and current challenges and opportunities of API, with the aim of providing direction and rationale for the further development and clinical application of API in the food, pharmaceutical and nutraceutical fields.
引用
收藏
页数:31
相关论文
共 208 条
[81]   Bioinspired and biomimetic micro- and nanostructures in biomedicine [J].
Johnson, Asha P. ;
Sabu, Chinnu ;
Nivitha, K. P. ;
Sankar, Renu ;
Shirin, V. K. Ameena ;
Henna, T. K. ;
Raphey, V. R. ;
Gangadharappa, H., V ;
Kotta, Sabna ;
Pramod, K. .
JOURNAL OF CONTROLLED RELEASE, 2022, 343 :724-754
[82]   Apigenin Ameliorates Dyslipidemia, Hepatic Steatosis and Insulin Resistance by Modulating Metabolic and Transcriptional Profiles in the Liver of High-Fat Diet-Induced Obese Mice [J].
Jung, Un Ju ;
Cho, Yun-Young ;
Choi, Myung-Sook .
NUTRIENTS, 2016, 8 (05)
[83]   The role of extracellular vesicles in cancer [J].
Kalluri, Raghu ;
McAndrews, Kathleen M. .
CELL, 2023, 186 (08) :1610-1626
[84]   Doxorubicin-An Agent with Multiple Mechanisms of Anticancer Activity [J].
Kciuk, Mateusz ;
Gielecinska, Adrianna ;
Mujwar, Somdutt ;
Kolat, Damian ;
Kaluzinska-Kolat, Zaneta ;
Celik, Ismail ;
Kontek, Renata .
CELLS, 2023, 12 (04)
[85]   Sorafenib: A Review in Hepatocellular Carcinoma [J].
Keating, Gillian M. .
TARGETED ONCOLOGY, 2017, 12 (02) :243-253
[86]   Crosstalk of liver immune cells and cell death mechanisms in different murine models of liver injury and its clinical relevance [J].
Khan, Hilal Ahmad ;
Ahmad, Muhammad Zishan ;
Khan, Junaid Ali ;
Arshad, Muhammad Imran .
HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL, 2017, 16 (03) :245-256
[87]   Modulation of Insulin Resistance in Nonalcoholic Fatty Liver Disease [J].
Khan, Reenam S. ;
Bril, Fernando ;
Cusi, Kenneth ;
Newsome, Philip N. .
HEPATOLOGY, 2019, 70 (02) :711-724
[88]   Apigenin induces apoptosis in Hep G2 cells:: Possible role of TNF-α and IFN-γ [J].
Khan, TH ;
Sultana, S .
TOXICOLOGY, 2006, 217 (2-3) :206-212
[89]   A mechanism of apigenin-induced apoptosis is potentially related to anti-angiogenesis and anti-migration in human hepatocellular carcinoma cells [J].
Kim, Bo Ra ;
Jeon, Young Keul ;
Nam, Myeong Jin .
FOOD AND CHEMICAL TOXICOLOGY, 2011, 49 (07) :1626-1632
[90]   Protective effect of linarin against D-galactosamine and lipopolysaccharide-induced fulminant hepatic failure [J].
Kim, Seok-Joo ;
Cho, Hong-Ik ;
Kim, So-Jin ;
Park, Jin-Hyun ;
Kim, Joon-Sung ;
Kim, Young Ho ;
Lee, Sang Kook ;
Kwak, Jong-Hwan ;
Lee, Sun-Mee .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2014, 738 :66-73